The Effects of ERCCl Expression Levels on the Chemo-resistance of Breast Cancer Patients Treated with Platinum-based Adjuvant Chemotherapy

Excision repair cross-complementing 1 (ercc1) is reported to be involved in the sensitivity of cancer patients to platinum-based chemotherapy. The present study to evaluate the effects of ERCC1 expression on the chemosensitivity of platinum agents in breast cancer. ercc1 expression levels were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The results demonstrated patients with low ercc1 levels had chemosensitive than those with high ercc1 levels. These results suggest that overexpression of ercc1 is correlated with platinum drug resistance in breast cancer patients .The patients with low levels of ercc1 expression demonstrate a benefit from platinum-based adjuvant chemotherapy.